K Dane Wittrup
Overview
Explore the profile of K Dane Wittrup including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
170
Citations
7164
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Santollani L, Maiorino L, Zhang Y, Palmeri J, Stinson J, Duhamel L, et al.
Nat Immunol
. 2024 Aug;
25(10):1820-1829.
PMID: 39112631
Systemically administered cytokines are potent immunotherapeutics but can cause severe dose-limiting toxicities. To overcome this challenge, cytokines have been engineered for intratumoral retention after local delivery. However, despite inducing regression...
2.
Hoffman M, Krum D, Wittrup K
J Biol Chem
. 2024 Aug;
300(9):107616.
PMID: 39089586
Targeted protein degradation is an emergent and rapidly evolving therapeutic strategy. In particular, biologics-based targeted degradation modalities (bioPROTACs) are relatively under explored compared to small molecules. Here, we investigate how...
3.
Mehta N, Rakhra K, Meetze K, Li B, Momin N, Chang J, et al.
Cancer Immunol Res
. 2024 Jun;
12(8):1022-1038.
PMID: 38842347
Despite clinical evidence of antitumor activity, the development of cytokine therapies has been hampered by a narrow therapeutic window and limited response rates. Two cytokines of high interest for clinical...
4.
Grzywa T, Mehta N, Cossette B, Romanov A, Paruzzo L, Ramasubramanian R, et al.
bioRxiv
. 2024 Apr;
PMID: 38659938
Chimeric antigen receptor (CAR) T cell therapy targeting CD19 elicits remarkable clinical efficacy in B-cell malignancies, but many patients relapse due to failed expansion and/or progressive loss of CAR-T cells....
5.
Palmeri J, Lax B, Peters J, Duhamel L, Stinson J, Santollani L, et al.
Nat Commun
. 2024 Mar;
15(1):1900.
PMID: 38429261
Although co-stimulation of T cells with agonist antibodies targeting 4-1BB (CD137) improves antitumor immune responses in preclinical studies, clinical success has been limited by on-target, off-tumor activity. Here, we report...
6.
Stinson J, Barbosa M, Sheen A, Momin N, Fink E, Hampel J, et al.
bioRxiv
. 2024 Feb;
PMID: 38405716
The clinical use of interleukin-2 and -12 cytokines against cancer is limited by their narrow therapeutic windows due to on-target, off-tumor activation of immune cells when delivered systemically. Engineering IL-2...
7.
Santollani L, Zhang Y, Maiorino L, Palmeri J, Stinson J, Duhamel L, et al.
bioRxiv
. 2024 Jan;
PMID: 38260254
Cytokine therapies are potent immunotherapy agents but exhibit severe dose-limiting toxicities. One strategy to overcome this involves engineering cytokines for intratumoral retention following local delivery. Here, we develop a localized...
8.
Hoffman M, Cheah K, Wittrup K
ACS Synth Biol
. 2024 Jan;
13(1):220-229.
PMID: 38171010
Targeted protein degradation offers a promising avenue for expanding therapeutic development to previously inaccessible proteins of interest by regulating the target abundance rather than activity. However, current methods to screen...
9.
Alvarez Calderon F, Kang B, Kyrysyuk O, Zheng S, Wang H, Mathewson N, et al.
Blood
. 2023 Dec;
143(12):1124-1138.
PMID: 38153903
The CD161 inhibitory receptor is highly upregulated by tumor-infiltrating T cells in multiple human solid tumor types, and its ligand, CLEC2D, is expressed by both tumor cells and infiltrating myeloid...
10.
Battula S, Papastoitsis G, Kaufman H, Wittrup K, Schmidt M
JCI Insight
. 2023 Dec;
8(23).
PMID: 38063196
IL-12 is a potent cytokine that can promote innate and adaptive anticancer immunity, but its clinical development has been limited by toxicity when delivered systemically. Intratumoral (i.t.) administration can expand...